In 2016, Polpharma Biologics acquired Dutch-based Bioceros and their proprietary cell line development platform CHOBC, as well as their comprehensive discovery, process development and analytical capabilities. Polpharma Biologics is now taking a further step and integrating Bioceros’ Utrecht site and their advanced cell line development capabilities fully into an already extensive biologics development and manufacturing offering, and retiring the Bioceros name. This change makes Polpharma Biologics a truly integrated CDMO, offering the complete spectrum of services from discovery to commercial supply.
 
The cell line development platform offered by Bioceros offers comprehensive services for both the development of novel biologics and biosimilars using their proprietary cell line, which was developed by the team with over 25 years of experience in generating high-yield production cell lines.
 
Polpharma Biologics have also now brought their state-of-the-art large-scale manufacturing plant in Warsaw fully under their brand. The site, which is now in the final stages of completion, will initially add four single-use bioreactor trains offering drug substance manufacturing at 500 – 2000 L scales, this adds to their existing manufacturing capacity and will be ready for clinical and commercial supply in 2021. The site has been designed for rapid expansion of capacity when needed, with space for a further six 2000 L bioreactors.
 
“The full integration of Bioceros’ capabilities into Polpharma Biologics and the additional drug substance capacity soon to be available in Warsaw complements the already significant services we can provide to our clients,” said Joerg Windisch, chief executive officer, Polpharma Biologics. “We can now support them from concept through development and to clinical and commercial scales.”